4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group cut their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Barclays dropped their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Bank of America dropped their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, June 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $4.10 on Thursday. The stock’s 50 day moving average is $3.78 and its 200 day moving average is $4.21. The firm has a market cap of $189.72 million, a P/E ratio of -1.29 and a beta of 2.81. 4D Molecular Therapeutics has a one year low of $2.24 and a one year high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. Equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of the company. Decheng Capital LLC raised its position in shares of 4D Molecular Therapeutics by 0.5% during the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock worth $2,228,000 after purchasing an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of 4D Molecular Therapeutics by 7.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock worth $247,000 after purchasing an additional 2,925 shares during the period. PNC Financial Services Group Inc. raised its position in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares during the period. Rhumbline Advisers raised its position in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after purchasing an additional 3,675 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 30.1% during the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock worth $91,000 after purchasing an additional 3,783 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.